Arcturus Therapeutics Holdings Inc - Asset Resilience Ratio
Arcturus Therapeutics Holdings Inc (ARCT) has an Asset Resilience Ratio of 0.20% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2018)
This chart shows how Arcturus Therapeutics Holdings Inc's Asset Resilience Ratio has changed over time. Check ARCT capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Arcturus Therapeutics Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Arcturus Therapeutics Holdings Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $920.00K | 0.2% |
| Total Liquid Assets | $920.00K | 0.20% |
Asset Resilience Insights
- Limited Liquidity: Arcturus Therapeutics Holdings Inc maintains only 0.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Arcturus Therapeutics Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Arcturus Therapeutics Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896 |
Biotechnology | 12.69% |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399 |
Biotechnology | 37.23% |
Annual Asset Resilience Ratio for Arcturus Therapeutics Holdings Inc (2011–2018)
The table below shows the annual Asset Resilience Ratio data for Arcturus Therapeutics Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $44.20 Million | -- |
| 2017-12-31 | 45.38% | $23.61 Million | $52.02 Million | -47.58pp |
| 2016-12-31 | 92.96% | $47.94 Million | $51.57 Million | +45.50pp |
| 2015-12-31 | 47.46% | $34.02 Million | $71.68 Million | -40.01pp |
| 2014-12-31 | 87.47% | $19.52 Million | $22.32 Million | +31.82pp |
| 2013-12-31 | 55.66% | $28.01 Million | $50.32 Million | +12.72pp |
| 2011-12-31 | 42.94% | $517.00K | $1.20 Million | -- |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more